Ascendis Pharma A/S (ASND)
Nasdaq: ASND · Pharmaceutical Preparations · filing with the SEC since 2014
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 202676 patents granted to the 11 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ascendis Pharma A/S’s names, not what it holds today.
Patents granted
76
74 utility, 2 design, 1976 to Dec 31, 2025
Granted in 2025
17
Against 11 in 2024 and 9 in 2023
Applications published
156
22 of them in 2025
Names they are printed under
11
its own name, a subsidiary
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals36
Medical technology15
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name11 counted
ASCENDIS PHARMA A/S its own name
DK, as the owner printed on each patent. 3 more under the same name are not counted (printed in DE)
32 published
Ascendis Pharma A/S its own name
named as the applicant on its applications, in DK. 3 more under the same name are not counted (printed in DE, printed in US)
48 published
ASCENDIS PHARMA GROWTH DISORDERS A/S a subsidiary
named as the applicant on its applications, in DK
21 published
ASCENDIS PHARMA GROWTH DISORDERS A/S a subsidiary
DK, as the owner printed on each patent
8 published
ASCENDIS PHARMA BONE DISEASES A/S a subsidiary
DK, as the owner printed on each patent
8 published
ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S a subsidiary
DK, as the owner printed on each patent. 1 more under the same name are not counted (printed in DE)
8 published
ASCENDIS PHARMA BONE DISEASES A/S a subsidiary
named as the applicant on its applications, in DK
15 published
Ascendis Pharma Oncology Division A/S a subsidiary
named as the applicant on its applications, in DK
9 published
ASCENDIS PHARMA ONCOLOGY DIVISION A/S a subsidiary
DK, as the owner printed on each patent
2 published
Ascendis Pharma Ophthalmology Division A/S a subsidiary
named as the applicant on its applications, in DK
3 published
Ascendis Pharma Endocrinology Division A/S a subsidiary
named as the applicant on its applications, in DK. 1 more under the same name are not counted (printed in DE)
2 published
Names not counted (1)
Ascendis Pharma A/S
Most of its patents print DE; this name counts in DK. 4 granted and 3 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Oct 28, 2025 | 12,453,778 | Incremental dose finding in controlled-release PTH compounds | Pharmaceuticals | ASCENDIS PHARMA BONE DISEASES A/S |
| Sep 30, 2025 | 12,428,461 | Treating cancer with a conjugate comprising an IL-2 moiety | Pharmaceuticals | ASCENDIS PHARMA ONCOLOGY DIVISION A/S |
| Sep 2, 2025 | 12,403,182 | Liquid pharmaceutical formulations of PTH conjugates | Pharmaceuticals | ASCENDIS PHARMA BONE DISEASES A/S |
| Aug 26, 2025 | D1,090,824 | Injector with cover | ASCENDIS PHARMA A/S | |
| Aug 12, 2025 | 12,383,676 | Auto injector with charger safety | Medical technology | ASCENDIS PHARMA A/S |
| Aug 5, 2025 | 12,377,133 | Dry pharmaceutical formulations of CNP conjugates | Pharmaceuticals | ASCENDIS PHARMA GROWTH DISORDERS A/S |
| May 20, 2025 | 12,303,553 | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin | Pharmaceuticals | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S |
| May 13, 2025 | 12,296,148 | Auto injector with temperature control | Medical technology | ASCENDIS PHARMA A/S |
| May 13, 2025 | 12,295,989 | Controlled-release PTH compound | Pharmaceuticals | ASCENDIS PHARMA BONE DISEASES A/S |
| May 6, 2025 | 12,290,663 | Front loaded auto injector for administering a medicament | Medical technology | ASCENDIS PHARMA A/S |
Newest applications publishedan application is a clue, never a plan
What it applied for, 2024 to 2025: Pharmaceuticals 25 · Medical technology 9.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.